CARTESIAN (RNAC)
$10.61
0.50 (4.71%)
RNAC Stock Quote Delayed 30 Minutes
RNAC Stock Earnings: Cartesian Therapeutics Beats EPS, Beats Revenue for Q2 2024
RNAC stock results show that Cartesian Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
$10.00
Market Cap
259.07M
PE Ratio
-2.37
EPS
-4.4769
Volume (Avg. Vol.)
170,854
Day's Range
$9.02 - $10.21
52-Week Range
$9.02 - $41.87
Dividend & Yield
N/A (N/A)
